During a panel session at the recent LSX World Congress industry spectators discussed the state of biopharma investing and how companies can prepare now for the return of the public markets.
Preparing For The Return Of Public Markets
Biotech investment is in abeyance after an unprecedented twelve-year run, according to Gregg Beloff, managing director of Danforth Advisors. The capital markets will be back and industry must continue to operate while the bear market persists.
